Not logged in Share Save
The Lancet Breast Cancer Commission Coles, Charlotte E.; Earl, Helena; Anderson, Benjamin O.; Barrios, Carlos H.; Bienz, Maya; Bliss, Judith M.; Cameron, David A.; Cardoso, Fatima; Cui, Wanda; Francis, Prudence A.; Jagsi, Reshma; Knaul, Felicia Marie; Mcintosh, Stuart A.; Phillips, Kelly-Anne; Radbruch, Lukas; Thompson, Mareike K.; Andre, Fabrice; Abraham, Jean E.; Bhattacharya, Indrani S.; Franzoi, Maria Alice; Drewett, Lynsey; Fulton, Alexander; Kazmi, Farasat; Rajah, Dharrnesha Inbah; Mutebi, Miriam; Ng, Dianna; Ng, Szeyi; Olopade, Olufunmilayo, I; Rosa, William E.; Rubasingham, Jeffrey; Spence, Dingle; Stobart, Hilary; Enciso, Valentina Vargas; Vaz-Luis, Ines; Villarreal-Garza, Cynthia Share Save
Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors Cook, Natalie; Blagden, Sarah; Lopez, Juanita; Sarker, Debashis; Greystoke, Alastair; Haris, Noor Md; Kazmi, Farasat; Anam, Kaiser; Franco, Ana Ortego; Pihlak, Rille; Goodwin, Louise; Wilson, David; Phillips, Caroline; Robertson, Jane; Timmis, Helen; Tilston, Craig; Woodcock, Simon A.; Plummer, Ruth Share Save
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301) Spiliopoulou, Pavlina; Kazmi, Farasat; Aroldi, Francesca; Holmes, Thomas; Thompson, David; Griffiths, Lucinda; Qi, Cathy; Parkes, Matthew; Lord, Simon; Veal, Gareth J.; Harrison, David J.; Coyle, Vicky M.; Graham, Jill; Jeffry Evans, Thomas R.; Blagden, Sarah P. Share Save
A phase Ib study of NUC-3373, a targeted inhibitor of thymidylate synthase, in combination with standard therapies in patients with advanced colorectal cancer (NuTide:302) Berlin, J.; Coveler, A. L.; Ciombor, K. K.; Kazmi, F.; Graham, J.; Peters, M. L.; Clark, J. W.; Myers, M.; De Gramont, A.; Evans, T. R. J.; Blagden, S. Share Save
A first-in-human study of NUC-7738, a ProTide transformation of 3′-deoxyadenosine, in patients with advanced solid tumours (NuTide:701) Blagden, S.; Haris, N. M.; Boh, Z.; Kazmi, F.; Aroldi, F.; Myers, M.; Symeonides, S. N.; Plummer, R. Share Save
Phase I study of the porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumours Cook, N.; Blagden, S.; Lopez, J.; Sarker, D.; Greystoke, A.; Harris, N.; Kazmi, F.; Naderi, A.; Nintos, G.; Franco, A. Ortego; Pihlak, R.; Shinde, R.; Goodwin, L.; Phillips, C.; Robertson, J.; Saunders, A.; Tilston, C.; Woodcock, S.; Plummer, R. Share Save
Results of a first-in-human study of the ProTide thymidylate synthase inhibitor NUC-3373, in patients with advanced solid tumours (NuTide:301) Spiliopoulou, P.; Kazmi, F.; Aroldi, F.; Holmes, J.; Graham, J.; Holmes, T.; Lord, S.; Veal, G.; Qi, C.; Coyle, V. M.; Evans, T. R. J.; Blagden, S. Share Save
A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma Booth, Stephen W.; Eyre, Toby A.; Whittaker, John; Campo, Leticia; Wang, Lai Mun; Soilleux, Elizabeth; Royston, Daniel; Rees, Gabrielle; Kesavan, Murali; Hildyard, Catherine; Kazmi, Farasat; La Thangue, Nick; Kerr, David; Middleton, Mark R.; Collins, Graham P. Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Not logged in.png){kind=icon}